Context to Present CT-202 Preclinical Nectin-4 × CD3 TCE Data at April 21 AACR Meeting
Context Therapeutics will showcase preclinical data on its pH-dependent Nectin-4 × CD3 bispecific antibody CT-202 at the AACR Annual Meeting on April 21, 9:00–12:00 PT (Abstract #5392). The poster highlights CT-202’s tumor-selective T cell engaging mechanism targeting Nectin-4 overexpressed in bladder, colorectal, lung and breast cancers.
1. Poster Presentation Details
On April 21, 2026 from 9:00 a.m. to 12:00 p.m. PT, Context Therapeutics will present Abstract #5392 titled “Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202” in Clinical Research Session PO.CL05.12 at the AACR Annual Meeting. The poster will be displayed in Poster Section 48 and available on the company’s website at the session start.
2. About CT-202 Asset
CT-202 is a bispecific antibody that engages CD3 on T cells and targets Nectin-4, a protein frequently overexpressed in bladder, colorectal, lung and breast tumors. Its pH-dependent design aims to activate selectively within the acidic tumor microenvironment, potentially reducing off-tumor toxicity compared to traditional ADCs targeting Nectin-4.
3. Context Therapeutics Pipeline
Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. Alongside CT-202, its pipeline includes CTIM-76 (Claudin 6 × CD3 TCE) and CT-95 (Mesothelin × CD3 TCE), advancing towards first-in-human studies from its Philadelphia headquarters.